Please assess the completion status of the following clinical trial:

Trial Title: Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. established diagnosis of spinal degenerative disease indicated for lumbar spine surgery,~2. patients indicated for fusion therapy,~3. patients between 18-55 years, both sexes,~4. patients able to provide written informed consent.~Exclusion Criteria:~1. previous lumbar spine surgery in the same segment of the spine, in order to achieve vertebral fusion,~2. osteoporosis,~3. diabetes mellitus,~4. pregnancy or breastfeeding,~5. women of childbearing potential not using effective contraception (established oral contraception, intrauterine device, ligation of the uterine tube) including proven contraceptive measures taken by their sexual partners,~6. fertile men not using proven contraceptive measures including effective contraception method in their partner (established oral contraception, intrauterine device, ligation of the uterine tube),~7. coagulopathy,~8. malnutrition, primary biliary cirrhosis,~9. skin infection at the site of bone marrow aspiration or at the site of spinal fusion,~10. gastrostomy,~11. any significant medical condition that would compromise the safety of the patient (e.g. recent myocardial infarction, congestive heart failure, renal failure, liver failure, systemic infection, recurrent thromboembolic disease .....),~12. alcohol or drug abuse,~13. cancer (compulsory clinical oncological screening),~14. ongoing or recent (last 3 months) systemic corticosteroid or immunosuppressive therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Human AMSC (passage 3) 3P in 1.5 mL (Type: EXPERIMENTAL): Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).